MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...

Sight Sciences Inc SGHT released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis for dry eye disease. TearCare is ...

DEAR DR. ROACH: My wife, who's 72, has had very dry eyes for a long time, so she uses Restasis (cyclosporine emulsion 0.05%) eye drops. Her co-pay (after meeting the deductible) last year was around ...

MENLO PARK, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and ...

DUBLIN--(BUSINESS WIRE)--The "Global Dry Eye Disease (DED) Market (by Type, Product, Treatment, Distribution Channel & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" ...

Dear Dr. Roach: My wife, who’s 72, has had very dry eyes for a long time, so she uses Restasis (cyclosporine emulsion 0.05%) eye drops. Her co-pay (after meeting the deductible) last year was around ...

MENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...